Clinical trials: Mixed Dyslipidaemia
Lipid Metabolism Disorders
Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
This study is to demonstrate therapeutic comparability of Fluvastatin sodium Extended Release Tablets 80 mg QD and Fluvastatin sodium Immediate Release Capsules 40 mg BID in LDL-C lowering from baseline to week 12 (endpoint) in…
- Trial name
- NCT01551173
- Testing
- Fluvastatin sodium
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Novartis Pharmaceuticals
Dyslipidemias
Phase 3 Trial to Evaluate the Efficacy and Safety of DKP21102_B Added on to DKP21102_A Compared With DKP21102_A
Phase 3 study to evaluate the efficacy and safety of DKP21102_B Added on to DKP21102_A Compared with DKP21102_A
- Trial name
- NCT05809687
- Testing
- DKP21102_C, DKP21102_B, DKP21102_A
- Sponsor
- Dongkwang Pharm. Co., Ltd.
HIV Infections, Hyperlipidemia
Effects of Mixed Exercise Regime and L-Carnitine Supplementation in HIV Patients on HAART
HIV patients treated with Highly Active AntiRetroviral Therapy (HAART) show significant metabolic symptoms, such as lipodystrophy, dyslipidemia, and insulin resistance.
- Conditions
- HIV Infections, Hyperlipidemia, Exercise
- Trial name
- HIV (NCT00572429)
- Testing
- l-carnitine
- Where
- United States
- Sponsor
- University of California, Davis
Primary Hyperlipidemia and Mixed Dyslipidemia
Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
This is a randomized, double-blind, placebo-controlled trial to evaluate the effect of evolocumab, atorvastatin, and combination therapy on lipoprotein kinetics.
- Trial name
- FLOREY (NCT02189837)
- Testing
- Evolocumab, Atorvastatin
- Where
- 2 sites in Australia
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Amgen
Dyslipidemia
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
Primary Objective: To demonstrate the superiority of alirocumab in comparison with usual care in the reduction of non-high-density lipoprotein cholesterol (non-HDL-C) in participants with type 2 diabetes and mixed dyslipidemia at…
- Trial name
- NCT02642159
- Testing
- Alirocumab, Statins, Ezetimibe
- Where
- 119 sites in United States, Australia and 13 more
- Volunteers
- 413 people
- Sponsor
- Sanofi
Hyperlipidemia, Mixed Dyslipidemia
An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)
To demonstrate that niacin ER and simvastatin (NS) tablets, when compared to atorvastatin (Lipitor®; Pfizer, Inc.), has superior high-density lipoprotein cholesterol (HDL-C) elevating effects at Week 12 in subjects with type II…
- Trial name
- SUPREME (NCT00465088)
- Testing
- Niacin ER/Simvastatin Tablets, atorvastatin
- Where
- 46 sites in United States
- Volunteers
- 199 people
- Sponsor
- Abbott
Hyperlipidemia; Mixed
Investigate the Effect of Ezetimibe, Simvastatin, and Omega 3- Fatty Acids on Dyslipidemia Patients: a Pharmacokinetics Based Study
This randomized controlled pharmacokinetic based study will be carried out on patients with both sexes and various ages, plasma triglycerides levels, clinical health disorders and using different agents for treatment of their…
- Trial name
- NCT05080140
- Testing
- Ezetimibe 10mg
- Where
- Egypt
- Volunteers
- 3 people
- Sponsor
- Misr University for Science and Technology
Primary Hypercholesterolemia, Mixed Dyslipidemias
Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
The study is to evaluate whether the efficacy of 1PC111 is superior to pitavastatin and ezetimibe in patients with primary hypercholesterolemia or mixed dyslipidemia in the 12 week treatment period.
- Trial name
- NCT04643093
- Testing
- Pitavastatin, Ezetimibe, 1PC111
- Where
- 34 sites in Australia, New Zealand and 1 more
- Volunteers
- 390 people
- Sponsor
- Orient Pharma Co., Ltd.
Hypercholesterolaemia, Mixed Dyslipidaemia
Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions.
Single dose oral bioequivalence study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated tablets in healthy adult human subjects under fasting conditions.
- Conditions
- Hypercholesterolaemia, Mixed Dyslipidaemia, Cardiovascular Diseases
- Trial name
- NCT06923956
- Testing
- Bempedoic Acid Film Coated Tablet, Nilemdo® (Bempedoic Acid) Film-coated tablets
- Where
- India
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Mixed Dyslipidemia
An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia
The primary objective of this study is to compare the effect of simvastatin plus Omacor to simvastatin plus placebo for lowering non-high density lipoprotein cholesterol in subjects with mixed dyslipidemia.
- Trial name
- NCT00487591
- Testing
- Omacor (omega-3-acid ethyl esters)plus simvastatin
- Volunteers
- 40 people
- Sponsor
- Provident Clinical Research
Mixed Dyslipidemia
A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe
Post-marketing surveillance of Rosuvastatin/Ezetimibe
- Trial name
- NCT03648788
- Testing
- NA (Observation study)
- Volunteers
- 600 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Hyperlipidemia and Mixed Dyslipidemia
Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia
This study will contribute to the evaluation of long-term safety, tolerability and efficacy of evolocumab (AMG 145) in adults with hyperlipidemia and adults with mixed dyslipidemia.
- Trial name
- OSLER-2 (NCT01854918)
- Testing
- Evolocumab, Standard of Care
- Where
- 363 sites in United States, Australia and 23 more
- Volunteers
- 3,681 people
- Sponsor
- Amgen